Daniel Long Sells 15,000 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 15,000 shares of Septerna stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president directly owned 96,412 shares in the company, valued at $3,423,590.12. This trade represents a 13.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Septerna Stock Down 1.4%

NASDAQ:SEPN traded down $0.52 on Wednesday, hitting $36.05. The stock had a trading volume of 357,572 shares, compared to its average volume of 309,340. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -44.51 and a beta of 2.39. The company has a fifty day moving average price of $28.80 and a two-hundred day moving average price of $27.23. Septerna, Inc. has a 1-year low of $10.26 and a 1-year high of $37.99.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, analysts anticipate that Septerna, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SEPN shares. Wells Fargo & Company raised their target price on Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Truist Financial upped their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.78.

Institutional Trading of Septerna

Institutional investors have recently added to or reduced their stakes in the stock. Group One Trading LLC raised its position in Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new position in shares of Septerna during the fourth quarter worth $35,000. Russell Investments Group Ltd. purchased a new position in shares of Septerna during the third quarter worth $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna in the fourth quarter valued at $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Septerna in the fourth quarter valued at $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.